drugset / Trial / NCT00206180

NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

NCT00206180

Phase 4 Completed 120 enrolled AstraZeneca
RandomizedParallel-groupDouble-blind

Summary

The purpose of this study is to decide if controlling stomach acid is related to healing of erosive esophagitis after treatment with esomeprazole magnesium (NEXIUM®) 10 mg and 40 mg once daily.

Timeline

Start
2004-06
Primary completion
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 10 mg Oral
Subject Esomeprazole Small molecule 40 mg Oral